Literature DB >> 14732630

Transverse myelitis in systemic sclerosis.

Amir M Torabi1, Rahul K Patel, Gil I Wolfe, Charlece S Hughes, Dianne B Mendelsohn, Jaya R Trivedi.   

Abstract

BACKGROUND: Neurological involvement occurs rarely with systemic sclerosis (SSc). Only a few cases of transverse myelopathy have been reported in the setting of SSc.
OBJECTIVE: To describe a patient with SSc who developed transverse myelitis that improved during a course of immunosuppression.
RESULTS: A 30-year-old woman with SSc presented with subacute onset of bilateral lower extremity weakness and numbness. Results of magnetic resonance imaging and cerebrospinal fluid studies supported a diagnosis of transverse myelitis. The patient responded favorably to a course of corticosteroids and cyclophosphamide. No overlapping autoimmune disorders were evident. Clinical follow-up showed significant recovery, with resolution of radiological abnormalities.
CONCLUSION: Transverse myelitis can occur as a rare manifestation of SSc and may respond favorably to immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14732630     DOI: 10.1001/archneur.61.1.126

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  4 in total

1.  Systemic Sclerosis, Reversible Cerebral Vasoconstriction Syndrome, and NeuroMyelitis Optica in a Patient.

Authors:  Masoud Etemadifar; Mehdi Shafiei; Mehri Salari; Ali Modares Sadeghi; Mohammad Fakhrolmobasheri
Journal:  Case Reports Immunol       Date:  2022-07-12

2.  Demyelinating syndrome in systemic sclerosis and neuromyelitis optica.

Authors:  Khaled Deeb; Jessika Eby; Jose Labault-Santiago
Journal:  BMC Neurol       Date:  2019-10-14       Impact factor: 2.474

3.  Transverse Myelitis Associated with Anti-Ro (SSA) Autoantibodies: A Record of Two Cases.

Authors:  G Melikyan; M H Abdelrahman; A D'Suoza; N Akhtar; A N Elzouki; M Hammoudeh
Journal:  Case Rep Rheumatol       Date:  2012-11-13

Review 4.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.